TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2185404
Drug: Molsidomine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Molsidomine (2 X 8 mg/d)
Study: 2185404
Drug: Nifedipine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (3 X 20 mg/d) and acetylsalicylic acid (1 X 500 mg/d)
Study: 2185404
Drug: SIN‐I (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: SIN‐I (0.5 mg)
Study: 6113802
Drug: Cimetidine 200
Normalized name: cimetidine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 200 mg by intramuscular injection one hour before surgery
Study: 31396203
Drug: Pemphigus patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemphigus patients managed with systemic medications
Study: 28346569
Drug: 4x100,000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4x100,000 IU cholecalciferol every 2 weeks (treatment group)
Study: 23523254
Drug: Intravenous tezosentan
Normalized name: TEZOSENTAN
DrugBank: Tezosentan (DB06558)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tezosentan (5 mg/h during surgery and up to 24 hours afterwards at 1 mg/h)
Study: 11318966
Drug: Minidose warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minidose warfarin (1 mg/day)
Study: 11318966
Drug: Low hemoglobin
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low hemoglobin (<10.5 g/dL)
Study: 18415463
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg apazone
Study: 18415463
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 75 mg diclofenac and 600 mg apazone
Study: 18415463
Drug: Placebo (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (50 ml NaCl 0.9%)
Study: 3365857
Drug: High-dose food
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose food allergen intake (one egg and one litre of milk daily)
Study: 3365857
Drug: Low-dose food
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose food allergen intake (diet free from hens' egg and cows' milk)
Study: 29698111
Drug: Arachidonic acid
Normalized name: Arachidonic acid
DrugBank: Arachidonic Acid (DB04557)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arachidonic acid (ARA) supplementation, 1.5 g/day for 4 weeks
Study: 8230265
Drug: rIFN-gamma (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: rIFN-gamma (0.2 mg, 4 x 10(6) units) once a day, subcutaneously, for 6 months
Study: 3777908
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of ciprofloxacin (200 mg)
Study: 3777908
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of ciprofloxacin (200 mg)
Study: 27565897
Drug: AL +
Normalized name: Citracal + D
Approvals — FDA: no, EMA: no, PMDA: no
Description: AL + PQ (artemether-lumefantrine plus primaquine 0.25 mg/kg)
Study: 25040945
Drug: Sitagliptin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin (100 mg/day, 6 weeks)
Study: 20689074
Drug: SB‐681323, 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB‐681323, 7.5 mg daily for 28 days, starting 3 days before PCI
Study: 16491814
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose doxycycline (20 mg, twice a day)
Study: 16491814
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose doxycycline (200 mg, twice a day)
Study: 12397267
Drug: Patient-controlled sedation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled sedation (propofol 4.8 mg and alfentanil 12 microg per bolus, no loading dose, lockout time set at zero)
Study: 12397267
Drug: Intravenous sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sedation (diazemuls 0.1 mg/kg and meperidine 0.5 mg/kg, with further increases at the discretion of the endoscopist)
Study: 8649053
Drug: Early dose-intensive
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early dose-intensive ANT consolidation program
Study: 1960378
Drug: alpha-interferon (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha-interferon (90 million units per m2 total dose over 12 weeks)
Study: 30946704
Drug: Brexpiprazole 0.5
Normalized name: brexpiprazole 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brexpiprazole 0.5 to 3 mg/d (flexible dose) adjunct to current antidepressant treatment
Study: 29939770
Drug: Vitamins (C:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamins (C: 1 g/day, E: 400 IU/day)
Study: 26846283
Drug: Methotrexate subcutaneous
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate subcutaneous (MTX SC)
Study: 26846283
Drug: Methotrexate oral
Normalized name: methotrexate Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate oral (MTX OR)
Study: 24717626
Drug: Tadalafil 10
Normalized name: tadalafil 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 10 mg daily
Study: 8608069
Drug: Patient-controlled analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled analgesia (PCA) with morphine (1.5-2 mg with a lockout of 5-10 minutes on demand)
Study: 8608069
Drug: Intramuscular (i.m.)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (i.m.) morphine injection (0.15-0.2 mg/kg every 4 hours on demand)
Study: 799979
Drug: Lymecycline (204
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lymecycline (204 mg, two capsules twice daily)
Study: 799979
Drug: Amoxycillin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin (250 mg, three times daily)
Study: 28592276
Drug: Respiratory rate
Normalized name: respiratory rate measuring device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Respiratory rate of 5 acts/min with tidal volume of 2-3 ml/Kg of ideal body weight and positive end-expiratory pressure of 3-5 cmH2O during cardiopulmonary bypass
Study: 26390920
Drug: High-density subthreshold
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-density subthreshold micropulse laser treatment (HSML)
Study: 26390920
Drug: Half-dose PDT
Normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-dose PDT
Study: 21837752
Drug: BMS‐790052 (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS‐790052 (1, 10, 30, 60, or 100 mg once daily or 30 mg twice daily)
Study: 19293342
Drug: ARD-07 with
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARD-07 with food (0.5 mg/kg)
Study: 19293342
Drug: ARD-07 without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ARD-07 without food (0.5 mg/kg)
Study: 15693705
Drug: Extract A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extract A: caffeoylquinic acids equivalent to 107.0 mg caffeic acid and luteolin glycosides equivalent to 14.4 mg luteolin
Study: 15693705
Drug: Extract B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extract B: caffeoylquinic acids equivalent to 153.8 mg caffeic acid and luteolin glycosides equivalent to 35.2 mg luteolin
Study: 15693705
Drug: Luteolin administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luteolin administered as glucoside
Study: 11789734
Drug: Antifibrinolytic agents
Normalized name: ANTIFIBRINOLYTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antifibrinolytic agents (aprotinin, epsilon-aminocaproic acid)
Study: 15505645
Drug: Eusol solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eusol solution
Study: 10228190
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of infliximab per kilogram
Study: 10228190
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of infliximab per kilogram
Study: 15251577
Drug: dextroamphetamine sulfate
Normalized name: Dextroamphetamine Sulfate
DrugBank: Dextroamphetamine (DB01576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: dextroamphetamine sulfate (after nonamphetamine therapies)
Study: 15251577
Drug: dextroamphetamine sulfate
Normalized name: Dextroamphetamine Sulfate
DrugBank: Dextroamphetamine (DB01576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: dextroamphetamine sulfate (urinary excretion <75%)
Study: 15251577
Drug: dextroamphetamine sulfate
Normalized name: Dextroamphetamine Sulfate
DrugBank: Dextroamphetamine (DB01576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: dextroamphetamine sulfate (urinary excretion <55%)
Study: 2101059
Drug: Zopiclone (6.25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zopiclone (6.25, 8.75 and 11.25 mg)
Study: 2101059
Drug: Triazolam (0.1875,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam (0.1875, 0.375 and 0.5 mg)
Study: 6969081
Drug: Metocurine 0.45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metocurine 0.45 mg kg‐1
Study: 30472236
Drug: Abrilumab 70
Normalized name: Abrilumab
DrugBank: Abrilumab (DB15076)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abrilumab 70 mg
Study: 30472236
Drug: Abrilumab 210
Normalized name: Abrilumab
DrugBank: Abrilumab (DB15076)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abrilumab 210 mg
Study: 28702870
Drug: Hypnotic Suggestion
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypnotic Suggestion (n = 73)
Study: 26433959
Drug: Paclitaxel 90
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 90 mg/m(2), Cisplatin 40 mg/m(2)
Study: 26433959
Drug: Paclitaxel 90
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 90 mg/m(2), Cisplatin 50 mg/m(2)
Study: 26433959
Drug: Paclitaxel 105
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 105 mg/m(2), Cisplatin 50 mg/m(2)
Study: 26433959
Drug: Pelvic IMRT
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelvic IMRT with concurrent TP
Study: 24268211
Drug: Amiodarone (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone (600 mg/d for 10 days, then 200-400 mg/d until the end of the study)
Study: 21332299
Drug: Neurodevelopmental Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurodevelopmental Treatment (NDT)
Study: 19203392
Drug: 1500 mg
Normalized name: inulin 1500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg of metformin daily
Study: 9510365
Drug: MMC 40
Normalized name: MMC
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MMC 40 mg (retained in the bladder for 2 hours) once a week for 8 weeks (group A)
Study: 26576838
Drug: High-FPG group
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-FPG group (FPG cut-off of 93 mg/dl for males and 92 mg/dl for females)
Study: 22033466
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with cetuximab or cisplatin plus Ad/SA
Study: 22033466
Drug: Cetuximab (EGFR-targeting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetuximab (EGFR-targeting anticancer drug)
Study: 20436073
Drug: Low-dose infliximab
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose infliximab (IFX) 3 mg/kg at 0, 2, and 6 weeks
Study: 15247137
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid supplementation (1.2 mg) for 12 weeks
Study: 8424573
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg iv ketorolac twice, then 10 mg iv every 30 min as required, followed by 10 mg oral ketorolac every 4-6 h
Study: 8424573
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg oral ketorolac
Study: 8424573
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg codeine plus 600 mg acetaminophen (C+A) orally every 4-6 h
Study: 29499122
Drug: Reduced daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced daily movement for 10 days
Study: 27576780
Drug: Renal denervation
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renal denervation plus standardized stepped-care antihypertensive treatment
Study: 27576780
Drug: Standardized stepped-care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized stepped-care antihypertensive treatment alone
Study: 20019369
Drug: IVTA 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVTA 4 mg
Study: 1791932
Drug: Alcohol 0.6
Normalized name: benzyl alcohol 0.6 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol 0.6 g/kg
Study: 17475963
Drug: Radical RT
Normalized name: Campsis radicans flower extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radical RT plus chemotherapy (RT), n=21
Study: 15612617
Drug: Terbinafine 250
Normalized name: terbinafine 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine 250 mg tablets (formulation 1)
Study: 15612617
Drug: Terbinafine 250
Normalized name: terbinafine 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine 250 mg tablets (formulation 2)
Study: 11732720
Drug: Ketoconazole 400
Normalized name: ketoconazole 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole 400 mg single dose (Category I)
Study: 11732720
Drug: Ketoconazole 200
Normalized name: ketoconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole 200 mg daily for 10 days (Category II)
Study: 11732720
Drug: Fluconazole 400
Normalized name: fluconazole 400 MG in 200 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole 400 mg single dose (Category III)
Study: 11732720
Drug: Fluconazole 150
Normalized name: fluconazole 150 MG
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole 150 mg per week for 4 weeks (Category IV)
Study: 8593018
Drug: Isepamicin 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isepamicin 7.5 mg/kg once daily for 10 days
Study: 8593018
Drug: Isepamicin 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isepamicin 7.5 mg/kg twice daily for 10 days
Study: 12085979
Drug: Spironolactone therapy
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spironolactone therapy
Study: 22275397
Drug: Certoparin 3000
Normalized name: certoparin
DrugBank: Certoparin (DB09261)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Certoparin 3000 IU subcutaneously once daily for 6 months
Study: 22275397
Drug: Placebo subcutaneously
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo subcutaneously once daily for 6 months
Study: 19706577
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) therapy at a dose range of 33 to 67 microg/kg per day
Study: 15448286
Drug: Case management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Case management intervention with monthly contact by case managers
Study: 989378
Drug: Melatonin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (50 mg i.v.)
Study: 28377392
Drug: RT+TRT (Resistance
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT+TRT (Resistance Training + Testosterone Replacement Therapy)
Study: 30794084
Drug: TRT (Testosterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRT (Testosterone Replacement Therapy)
Study: 21450542
Drug: Endoscopist-administered propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Endoscopist-administered propofol sedation
Study: 21450542
Drug: Anaesthetist-administered deep
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anaesthetist-administered deep sedation
Study: 19575117
Drug: Topical adrenaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical adrenaline 1:2,000
Study: 19575117
Drug: Topical adrenaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical adrenaline 1:10,000
Study: 19575117
Drug: Topical adrenaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical adrenaline 1:50,000
Study: 17708740
Drug: Tocilizumab (anti-IL-6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab (anti-IL-6 receptor monoclonal antibody)
Study: 15140425
Drug: Biopharmaceuticals targeting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biopharmaceuticals targeting specific disease‐mediating molecules
Study: 1700551
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous gammaglobulin administration
Study: 791448
Drug: Increasing doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increasing doses of propranolol
Study: 23223507
Drug: Intra-arterial thrombolysis
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial thrombolysis (treatment arm)
Study: 16829095
Drug: C1-esterase inhibitor
Normalized name: HUMAN C1-ESTERASE INHIBITOR
DrugBank: Human C1-esterase inhibitor (DB06404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: C1-esterase inhibitor (C1‐INH) administration (40 IU kg(‐1) during reperfusion and 20 IU kg(‐1) 6 h postoperatively)
Study: 10587935
Drug: Morphine maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine maintenance
Study: 31274197
Drug: Pseudoephedrine hydrochloride
Normalized name: Pseudoephedrine Hydrochloride
DrugBank: Pseudoephedrine (DB00852)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pseudoephedrine hydrochloride 30-mg tablets
Study: 29032916
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg kg−1 epidural ropivacaine
Study: 29032916
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg kg−1 ropivacaine and 2 mg kg−1 magnesium sulphate
Study: 25942606
Drug: Oxycodone/Naloxone (OXN)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone/Naloxone (OXN)
Study: 25942606
Drug: Morphine (MOR)
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine (MOR)
Study: 1475988
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg famotidine administered twice daily for 4 weeks
Study: 1475988
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg famotidine administered once daily for 4 weeks
Study: 1475988
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg famotidine administered twice daily for 8 weeks
Study: 1475988
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg famotidine administered once daily for 8 weeks
Study: 25770144
Drug: Intravitreal ranibizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal ranibizumab injection (IVR)
Study: 25730933
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of peloid balneotherapy with magnetic laser therapy and application of efthidermum MPE to the lumbar region
Study: 20565460
Drug: Scopolamine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine (1.5 mg transdermal patch every 72 hours for 2 weeks)
Study: 20565460
Drug: Placebo (transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (transdermal patch every 72 hours for 2 weeks)
Study: 20565460
Drug: Scopolamine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine (1.5 mg transdermal patch)
Study: 7767515
Drug: Inhaled salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled salbutamol (300 micrograms)
Study: 2152662
Drug: Enalapril, 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril, 5 mg/day
Study: 7439251
Drug: Propranolol (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (160 mg initially, increased to 240 or 320 mg if necessary)
Study: 7439251
Drug: Metoprolol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (200 mg initially, increased to 300 or 400 mg if necessary)
Study: 31810781
Drug: Self-reported vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-reported vaccine coverage for seasonal influenza vaccine (recommended, 2016/17 season)
Study: 31810781
Drug: Self-reported vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-reported vaccine coverage for Bacillus Calmette-Guérin vaccine (mandatory)
Study: 31810781
Drug: Vaccine hesitancy
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine hesitancy prevalence rate
Study: 31810781
Drug: Vaccine hesitancy
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine hesitancy concerning seasonal influenza or A(H1N1) vaccines
Study: 31810781
Drug: Vaccine hesitancy
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine hesitancy concerning hepatitis B vaccine
Study: 31124581
Drug: Intensified CNS-directed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified CNS-directed therapy
Study: 31124581
Drug: Intensified induction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified induction chemotherapy
Study: 15090972
Drug: Intravenous GLP-1
Normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous GLP-1 (1.2 pmol x kg x min) for 8 hours
Study: 15090972
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion for 8 hours
Study: 11296544
Drug: NIM 200
Normalized name: L-pyroglutamyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-Nim-benzyl-histidyl-L-leucyl-L-arginyl-L-proline ethylamide
DrugBank: Histrelin (DB06788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NIM 200 mg/day
Study: 11296544
Drug: NIM 400
Normalized name: L-pyroglutamyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-Nim-benzyl-histidyl-L-leucyl-L-arginyl-L-proline ethylamide
DrugBank: Histrelin (DB06788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NIM 400 mg/day
Study: 11296544
Drug: NIM 100
Normalized name: L-pyroglutamyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-Nim-benzyl-histidyl-L-leucyl-L-arginyl-L-proline ethylamide
DrugBank: Histrelin (DB06788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NIM 100 mg/day
Study: 2956876
Drug: Enoximone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoximone (50 to 100 mg 3 times daily)
Study: 27208905
Drug: Intravenous trastuzumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous trastuzumab (8 mg/kg loading, 6 mg/kg maintenance)